Utility of the 2019 EULAR/ACR SLE classification criteria for predicting mortality and hospitalisation: development and cross-validation of ominosity score.
Gabriel Figueroa-Parra, Andrew C Hanson, Alain Sanchez-Rodriguez, Jose A Meade-Aguilar, Mariana González-Treviño, María C Cuéllar-Gutiérrez, Kamil E Barbour, Alí Duarte-García, Cynthia Crowson
{"title":"Utility of the 2019 EULAR/ACR SLE classification criteria for predicting mortality and hospitalisation: development and cross-validation of ominosity score.","authors":"Gabriel Figueroa-Parra, Andrew C Hanson, Alain Sanchez-Rodriguez, Jose A Meade-Aguilar, Mariana González-Treviño, María C Cuéllar-Gutiérrez, Kamil E Barbour, Alí Duarte-García, Cynthia Crowson","doi":"10.1136/rmdopen-2024-004833","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria score (≥20 points) has been associated with poor outcomes. We aimed to evaluate its utility as a predictor for mortality and hospitalisation and to derive and validate an ominosity score based on the SLE classification criteria set.</p><p><strong>Methods: </strong>Incident patients with SLE in a population-based cohort were included. The association between the 2019 EULAR/ACR SLE score and mortality and hospitalisation was assessed using Cox regression adjusted for age, sex and calendar year. An ominosity score for mortality was developed based on the SLE criteria set. The least absolute shrinkage and selection operator method was used to estimate model coefficients. Concordance and calibration were assessed by cross-validation and by plotting the observed event rates against the deciles of predicted probabilities.</p><p><strong>Results: </strong>Among 374 patients with incident SLE, a EULAR/ACR score ≥20 points was not associated with an increased risk of mortality (HR 1.17, 95% CI 0.67 to 2.03) or first hospitalisation (HR 1.14, 95% CI 0.79 to 1.64) compared with a score ≤19 points. The derived ominosity score for mortality included age, sex, thrombocytopaenia, neuropsychiatric manifestations, subacute cutaneous or discoid lupus, non-scarring alopecia, inflammatory arthritis, renal involvement, antiphospholipid antibodies and hypocomplementaemia. This model demonstrated a concordance=0.76 with adequate calibration. Age and sex were the main predictors, as seen in the model including just age, sex and year (concordance=0.77).</p><p><strong>Conclusion: </strong>The 2019 EULAR/ACR SLE criteria score was not associated with mortality and hospitalisation. The derived ominosity score for mortality presented good prediction for mortality but was not better than age and sex alone.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"10 4","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580311/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMD Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/rmdopen-2024-004833","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria score (≥20 points) has been associated with poor outcomes. We aimed to evaluate its utility as a predictor for mortality and hospitalisation and to derive and validate an ominosity score based on the SLE classification criteria set.
Methods: Incident patients with SLE in a population-based cohort were included. The association between the 2019 EULAR/ACR SLE score and mortality and hospitalisation was assessed using Cox regression adjusted for age, sex and calendar year. An ominosity score for mortality was developed based on the SLE criteria set. The least absolute shrinkage and selection operator method was used to estimate model coefficients. Concordance and calibration were assessed by cross-validation and by plotting the observed event rates against the deciles of predicted probabilities.
Results: Among 374 patients with incident SLE, a EULAR/ACR score ≥20 points was not associated with an increased risk of mortality (HR 1.17, 95% CI 0.67 to 2.03) or first hospitalisation (HR 1.14, 95% CI 0.79 to 1.64) compared with a score ≤19 points. The derived ominosity score for mortality included age, sex, thrombocytopaenia, neuropsychiatric manifestations, subacute cutaneous or discoid lupus, non-scarring alopecia, inflammatory arthritis, renal involvement, antiphospholipid antibodies and hypocomplementaemia. This model demonstrated a concordance=0.76 with adequate calibration. Age and sex were the main predictors, as seen in the model including just age, sex and year (concordance=0.77).
Conclusion: The 2019 EULAR/ACR SLE criteria score was not associated with mortality and hospitalisation. The derived ominosity score for mortality presented good prediction for mortality but was not better than age and sex alone.
目的:2019年欧洲风湿病学协会联盟(EULAR)/美国风湿病学会(ACR)系统性红斑狼疮(SLE)分类标准评分(≥20分)与不良预后有关。我们的目的是评估其作为死亡率和住院率预测指标的效用,并根据系统性红斑狼疮分类标准集得出和验证预兆评分:方法:纳入基于人群的队列中的系统性红斑狼疮患者。采用Cox回归法评估了2019年EULAR/ACR系统性红斑狼疮评分与死亡率和住院率之间的关系,并对年龄、性别和日历年进行了调整。根据系统性红斑狼疮标准集制定了死亡率预兆评分。采用最小绝对收缩和选择算子法估算模型系数。通过交叉验证以及将观察到的事件发生率与预测概率的十分位数进行对比,对一致性和校准进行了评估:在374名系统性红斑狼疮患者中,EULAR/ACR评分≥20分与评分≤19分相比,死亡率(HR 1.17,95% CI 0.67-2.03)或首次住院(HR 1.14,95% CI 0.79-1.64)风险并不增加。得出的死亡率预兆评分包括年龄、性别、血小板减少症、神经精神表现、亚急性皮肤或盘状狼疮、非瘢痕性脱发、炎性关节炎、肾脏受累、抗磷脂抗体和低补体血症。该模型的一致性=0.76,校准充分。年龄和性别是主要的预测因素,这一点在仅包括年龄、性别和年份的模型中可以看出(一致性=0.77):2019年EULAR/ACR系统性红斑狼疮标准评分与死亡率和住院率无关。得出的死亡率预兆评分能很好地预测死亡率,但并不优于单纯的年龄和性别。
期刊介绍:
RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.